共 50 条
- [31] An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphomaBLOOD, 2018, 132 (14) : 1486 - 1494Morschhauser, FranckSalles, GillesLe Gouill, StevenTilly, HerveThieblemont, CatherineBouabdallah, KrimoFabiani, BettinaMenard, CedricTarte, KarinCartron, GuillaumeHouot, Roch
- [32] Combination of CpG7909 and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL): A phase 1, open label dose-escalation study of safety and tolerability.JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 581S - 581SWeiner, GJLink, BKLeonard, JEmmanouilides, CAlbert, GSchmalbach, T
- [33] An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL) and Follicular Lymphoma (FL)BLOOD, 2015, 126 (23)Younes, AnasSalles, GillesMartinelli, GiovanniBociek, R. GregoryBarrigon, Dolores CaballeroGonzalez Barca, EvaTurgut, MehmetGerecitano, John F.Herbst, FabianWilliams, LisaMukherjee, NabanitaTavorath, RanjanaKim, Won Seog
- [34] An open-label, dose-escalation phase lb study of subcutaneous daratumumab with recombinant human hyaluronidase in patients with relapsed or refractory multiple myeloma (PAVO).JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Nahi, HarethHellemans, PeterMasterson, Tara J.Clemens, Pamela L.Ahmadi, TahamtanSan Miguel, JesusMateos, Maria-VictoriaUsmani, Saad Zafar
- [35] Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Including Patients with MYC AlterationsBLOOD, 2016, 128 (22)Landsburg, Daniel J.Ramchandren, RadhakrishnanHafeez, AmirGharavi, RobertChander, TaniaMa, AnnaBurch, Micah M.Oki, Yasuhiro
- [36] A Multicenter Open-Label, Phase 1b/2 Study of Ibrutinib in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)BLOOD, 2016, 128 (22)Goy, AndreRamchandren, RadhakrishnanGhosh, NilanjanMunoz, JavierMorgan, David S.Dang, Nam H.Knapp, MarkDelioukina, MariaKingsley, Edwin C.Anh TranPing, JerryBeaupre, Darrin M.Neuenburg, Jutta K.Ruan, Jia
- [37] OPROZOMIB (OPZ) AND DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED RESULTS FROM DOSE ESCALATION IN A PHASE 1B/2, MULTICENTER, OPEN-LABEL STUDYHAEMATOLOGICA, 2015, 100 : 254 - 255Hari, P.Shain, K. H.Voorhees, P.Gabrail, N.Abidi, M.Zonder, J.Boccia, R.Richardson, P. G.Neuman, L.Wong, H.Dixon, S.Prada, C. P.
- [38] A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphomaINVESTIGATIONAL NEW DRUGS, 2021, 39 (04) : 1028 - 1035Balzarotti, MonicaMagagnoli, MassimoCanales, Miguel AngelCorradini, PaoloGrande, CarlosSancho, Juan-ManuelZaja, FrancescoQuinson, Anne-MarieBelsack, ValerieMaier, DanielaCarlo-Stella, Carmelo
- [39] A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphomaInvestigational New Drugs, 2021, 39 : 1028 - 1035Monica BalzarottiMassimo MagagnoliMiguel Ángel CanalesPaolo CorradiniCarlos GrandeJuan-Manuel SanchoFrancesco ZajaAnne-Marie QuinsonValérie BelsackDaniela MaierCarmelo Carlo-Stella
- [40] A phase 1 adaptive dose-escalation study to evaluate the tolerability, safety, pharmacokinetics, and antitumor activity of ADCT-402 in patients with relapsed or refractory B-cell lineage non Hodgkin lymphoma (B-NHL).JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Chung, Ki Y.Hamadani, MehdiKahl, Brad S.Heffner, Leonard T.Caimi, Paolo FabrizioFeingold, Jay MarshallO'Connor, Owen A.